Inhibition of a triggering receptor expressed on myeloid cells-1 (TREM-1) with an extracellular cold-inducible RNA-binding protein (eCIRP)-derived peptide protects mice from intestinal ischemia-reperfusion injury.
Acute Lung Injury
/ drug therapy
Animals
Cytokines
/ metabolism
Disease Models, Animal
Drug Evaluation, Preclinical
Humans
Intestines
/ blood supply
Male
Mice
Peptide Fragments
/ immunology
RNA-Binding Proteins
/ immunology
Reperfusion Injury
/ complications
Signal Transduction
/ drug effects
Triggering Receptor Expressed on Myeloid Cells-1
/ antagonists & inhibitors
Journal
Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
07
02
2020
revised:
31
03
2020
accepted:
02
04
2020
pubmed:
23
5
2020
medline:
12
11
2020
entrez:
23
5
2020
Statut:
ppublish
Résumé
Intestinal ischemia-reperfusion injury results in morbidity and mortality from both local injury and systemic inflammation and acute lung injury. Extracellular cold-inducible RNA-binding protein is a damage associated molecular pattern that fuels systemic inflammation and potentiates acute lung injury. We recently discovered a triggering receptor expressed on myeloid cells-1 serves as a novel receptor for extracellular cold-inducible RNA-binding protein. We developed a 7-aa peptide, named M3, derived from the cold-inducible RNA-binding protein, which interferes with cold-inducible RNA-binding protein's binding to a triggering receptor expressed on myeloid cells-1. Here, we hypothesized that M3 protects mice against intestinal ischemia-reperfusion injury. Intestinal ischemia was induced in C57BL/6 mice via clamping of the superior mesenteric artery for 60 minutes. At reperfusion, mice were treated intraperitoneally with M3 (10 mg/kg body weight) or normal saline vehicle. Mice were killed 4 hours after reperfusion and blood and lungs were collected for various analysis. A 24-hours survival after intestinal ischemia-reperfusion was assessed. Serum levels of organ injury markers aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, and lactate were increased with intestinal ischemia-reperfusion, while treatment with M3 significantly decreased their levels. Serum, intestinal, and lung levels of proinflammatory cytokines and chemokines were also increased by intestinal ischemia-reperfusion, and treatment with M3 significantly reduced these values. Intestinal ischemia-reperfusion caused significant histological intestinal and lung injuries, which were mitigated by M3. Treatment with M3 improved the survival from 40% to 80% after intestinal ischemia-reperfusion. Inhibition of triggering receptor expressed on myeloid cells-1 by an extracellular cold-inducible RNA-binding protein-derived small peptide (M3) decreased inflammation, reduced lung injury, and improved survival in intestinal ischemia-reperfusion injury. Thus, blocking the extracellular cold-inducible RNA-binding protein-triggering receptor expressed on myeloid cells-1 interaction is a promising therapeutic avenue for mitigating intestinal ischemia-reperfusion injury.
Sections du résumé
BACKGROUND
Intestinal ischemia-reperfusion injury results in morbidity and mortality from both local injury and systemic inflammation and acute lung injury. Extracellular cold-inducible RNA-binding protein is a damage associated molecular pattern that fuels systemic inflammation and potentiates acute lung injury. We recently discovered a triggering receptor expressed on myeloid cells-1 serves as a novel receptor for extracellular cold-inducible RNA-binding protein. We developed a 7-aa peptide, named M3, derived from the cold-inducible RNA-binding protein, which interferes with cold-inducible RNA-binding protein's binding to a triggering receptor expressed on myeloid cells-1. Here, we hypothesized that M3 protects mice against intestinal ischemia-reperfusion injury.
METHODS
Intestinal ischemia was induced in C57BL/6 mice via clamping of the superior mesenteric artery for 60 minutes. At reperfusion, mice were treated intraperitoneally with M3 (10 mg/kg body weight) or normal saline vehicle. Mice were killed 4 hours after reperfusion and blood and lungs were collected for various analysis. A 24-hours survival after intestinal ischemia-reperfusion was assessed.
RESULTS
Serum levels of organ injury markers aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, and lactate were increased with intestinal ischemia-reperfusion, while treatment with M3 significantly decreased their levels. Serum, intestinal, and lung levels of proinflammatory cytokines and chemokines were also increased by intestinal ischemia-reperfusion, and treatment with M3 significantly reduced these values. Intestinal ischemia-reperfusion caused significant histological intestinal and lung injuries, which were mitigated by M3. Treatment with M3 improved the survival from 40% to 80% after intestinal ischemia-reperfusion.
CONCLUSION
Inhibition of triggering receptor expressed on myeloid cells-1 by an extracellular cold-inducible RNA-binding protein-derived small peptide (M3) decreased inflammation, reduced lung injury, and improved survival in intestinal ischemia-reperfusion injury. Thus, blocking the extracellular cold-inducible RNA-binding protein-triggering receptor expressed on myeloid cells-1 interaction is a promising therapeutic avenue for mitigating intestinal ischemia-reperfusion injury.
Identifiants
pubmed: 32439208
pii: S0039-6060(20)30191-4
doi: 10.1016/j.surg.2020.04.010
pmc: PMC7483826
mid: NIHMS1585952
pii:
doi:
Substances chimiques
Cirbp protein, mouse
0
Cytokines
0
Peptide Fragments
0
RNA-Binding Proteins
0
TREM1 protein, mouse
0
Triggering Receptor Expressed on Myeloid Cells-1
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
478-485Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL076179
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Dig Dis Sci. 2004 Sep;49(9):1359-77
pubmed: 15481305
J Leukoc Biol. 2019 Jul;106(1):133-146
pubmed: 30645013
Sci Rep. 2016 Feb 23;6:22044
pubmed: 26902261
Expert Opin Ther Pat. 2014 Dec;24(12):1383-95
pubmed: 25363248
Crit Care Med. 2018 Jun;46(6):e489-e495
pubmed: 29432347
Drug Discov Today. 2018 Jul;23(7):1416-1425
pubmed: 29857163
Am J Physiol Lung Cell Mol Physiol. 2016 Mar 1;310(5):L426-38
pubmed: 26684249
J Pediatr Surg. 2005 Mar;40(3):470-7
pubmed: 15793720
Am J Physiol Gastrointest Liver Physiol. 2015 Jan 15;308(2):G63-75
pubmed: 25414098
Nat Med. 2013 Nov;19(11):1489-1495
pubmed: 24097189
Crit Care Med. 2008 Feb;36(2):504-10
pubmed: 18091551
Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286(3):G452-7
pubmed: 14563675
Sci Rep. 2016 Dec 22;6:39473
pubmed: 28004759
Sci Rep. 2016 May 24;6:26571
pubmed: 27217302
Nat Med. 2011 Nov 07;17(11):1391-401
pubmed: 22064429
Am J Respir Cell Mol Biol. 2011 May;44(5):725-38
pubmed: 21531958
Life Sci. 2006 May 22;78(26):3058-65
pubmed: 16413039
Shock. 2007 Aug;28(2):227-38
pubmed: 17666944
Surgery. 2018 Dec;164(6):1191-1197
pubmed: 30154017
J Trauma Acute Care Surg. 2020 Jun;88(6):809-815
pubmed: 32453257
Surgery. 2017 Oct;162(4):917-927
pubmed: 28709648
J Pathol. 2000 Feb;190(3):255-66
pubmed: 10685060
World J Emerg Med. 2010;1(2):144-8
pubmed: 25214958
J Immunol. 2000 May 15;164(10):4991-5
pubmed: 10799849
Pharmacol Ther. 2017 Sep;177:81-95
pubmed: 28245991
Crit Care. 2005 Oct 5;9(5):485-9
pubmed: 16277737
FASEB J. 2020 Mar;34(3):4384-4402
pubmed: 31961020
J Immunol. 2008 Mar 1;180(5):3520-34
pubmed: 18292579
Front Mol Biosci. 2018 Nov 29;5:89
pubmed: 30555831
BMC Gastroenterol. 2019 May 30;19(1):80
pubmed: 31146693
Bioorg Med Chem. 2018 Jun 1;26(10):2700-2707
pubmed: 28720325
J Surg Res. 2002 Mar;103(1):61-7
pubmed: 11855919
Ann Surg. 2020 Dec;272(6):1070-1079
pubmed: 30614877
Sci Rep. 2018 Feb 28;8(1):3797
pubmed: 29491382
Mol Med Rep. 2017 Sep;16(3):2529-2537
pubmed: 28713893
J Trauma. 2008 May;64(5):1196-200; discussion 1200-1
pubmed: 18469641
Am J Respir Crit Care Med. 2010 Feb 1;181(3):238-46
pubmed: 19892861
Cell Death Differ. 2004 Jul;11 Suppl 1:S45-55
pubmed: 15243581
N Engl J Med. 2016 Mar 10;374(10):959-68
pubmed: 26962730
Nature. 2001 Apr 26;410(6832):1103-7
pubmed: 11323674
Pediatr Surg Int. 2008 Mar;24(3):337-41
pubmed: 17973111
Sci Rep. 2017 Jan 27;7:41363
pubmed: 28128330
Front Pharmacol. 2017 Jan 06;7:526
pubmed: 28111551
J Exp Med. 2004 Dec 6;200(11):1419-26
pubmed: 15557347
Eur J Trauma Emerg Surg. 2018 Apr;44(2):265-272
pubmed: 28612169
World J Gastroenterol. 2015 Jul 21;21(27):8314-25
pubmed: 26217083
Crit Care Med. 2000 Jul;28(7):2437-44
pubmed: 10921576
J Leukoc Biol. 2013 Feb;93(2):209-15
pubmed: 23108097
JCI Insight. 2020 Mar 12;5(5):
pubmed: 32027618
CMAJ. 2005 Feb 1;172(3):367-79
pubmed: 15684121